SAN JOSE, Calif., Aug. 17, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th. Dr. Kumar's presentation, "Liquid Biopsy based on Flow Cytometry and Artificial Intelligence to Detect the Existence of a Solid Tumor," is scheduled at 2:50 PM EDT, Wednesday, August 22nd. Dr. Kumar will discuss ITUS's latest data on its Cchek™ diagnostic development, including studies on breast cancer and prostate cancer, as well as data from the collaborative study with Memorial Sloan Kettering and Serametrix.
"This conference is focused on a number of diagnostic technologies including liquid biopsy and early cancer detection. This is the first commercial conference where we will be presenting our technology to a concentrated audience of industry players," stated Dr. Kumar. "We are pleased with the scientific progress achieved thus far with Cchek™, and we remain confident that we will begin preliminary regulatory discussions with the FDA by the end of the year," added Dr. Kumar.
Dr. Kumar further stated, "With both of our programs--Cchek™ cancer diagnostic and CAR-T treatment for ovarian cancer—heading toward initial FDA discussions by the end of the year, we are excited about the impact we could have on the fight against cancer. Any day now, we are expecting to hear back from the FDA regarding the request, by us and our partner Moffitt Cancer Center, for a pre-IND meeting about our CAR-T therapy. We believe that the next few months will be a very exciting period for the Company, for our shareholders, and for cancer patients."
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
SOURCE ITUS Corporation